{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:33:43Z","timestamp":1788820423521,"version":"build-2803163510"},"reference-count":27,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2024,6,25]]},"abstract":"<jats:p>Background: Plasma and cerebrospinal fluid (CSF) levels of p-tau181 have been associated with Alzheimer\u2019s disease (AD). The retina and vitreous have shown measurable quantities of phosphorylated tau 181 (p-tau181). The aqueous humor, which can be collected during cataract surgery, may have measurable concentrations of p-tau181. Objective: To determine whether p-tau181 is detectable in the aqueous humor and if so, whether it is associated with other measures that might be consistent with AD such as higher plasma p-tau181 concentration and lower Montreal Cognitive Assessment (MoCA-BLIND version 7.1) score. Methods: Aqueous humor samples, blood samples, and MoCA-BLIND scores were collected from patients who did not carry a clinical diagnosis of cognitive impairment at the time of cataract surgery. Aqueous p-tau181 concentrations and plasma p-tau181 concentrations were then measured using ultra-sensitive single-molecule assay ELISA technology. A rank-transformed mixed-effects multivariate regression model was used to determine associations between aqueous concentrations, plasma concentrations, and MoCA-BLIND scores. Results: 16 eyes of 16 participants were enrolled with an average age of 71.6. Average MoCA-BLIND score was 20.6\/22, average aqueous p-tau181 concentration was 6.4\u200apg\/mL, and average plasma p-tau181 concentration was 3.1\u200apg\/mL. Higher plasma p-tau181 was significantly associated with higher aqueous p-tau181 (p\u200a=\u200a0.02). Aqueous p-tau181 and plasma p-tau181 were negatively associated with MoCA-BLIND scores (p\u200a=\u200a0.005 and p\u200a=\u200a0.001 respectively) in these patients. Conclusions: Aqueous p-tau181 is positively correlated with plasma p-tau181 and is negatively correlated with MoCA-BLIND scores. Further study in individuals with mild cognitive impairment or AD characterized by cerebrospinal fluid and volumetric MRI metrics may yield further insights.<\/jats:p>","DOI":"10.3233\/jad-240279","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T11:27:22Z","timestamp":1717759642000},"page":"239-245","source":"Crossref","is-referenced-by-count":5,"title":["Aqueous and Plasma Levels of Phosphorylated Tau 181 in Individuals with Normal Cognition"],"prefix":"10.1177","volume":"100","author":[{"given":"Hemal","family":"Patel","sequence":"first","affiliation":[{"name":"iMIND Study Group, Duke University School of Medicine, Durham, NC, USA"},{"name":"Department of Ophthalmology, Duke University School of Medicine, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Ellis","family":"Wisely","sequence":"additional","affiliation":[{"name":"iMIND Study Group, Duke University School of Medicine, Durham, NC, USA"},{"name":"Department of Ophthalmology, Duke University School of Medicine, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cason B.","family":"Robbins","sequence":"additional","affiliation":[{"name":"iMIND Study Group, Duke University School of Medicine, Durham, NC, USA"},{"name":"Department of Ophthalmology, Duke University School of Medicine, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Parker","sequence":"additional","affiliation":[{"name":"Department of Neurology, Duke University School of Medicine, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratap","family":"Challa","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Duke University School of Medicine, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilraj S.","family":"Grewal","sequence":"additional","affiliation":[{"name":"iMIND Study Group, Duke University School of Medicine, Durham, NC, USA"},{"name":"Department of Ophthalmology, Duke University School of Medicine, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Fekrat","sequence":"additional","affiliation":[{"name":"iMIND Study Group, Duke University School of Medicine, Durham, NC, USA"},{"name":"Department of Ophthalmology, Duke University School of Medicine, Durham, NC, USA"},{"name":"Department of Neurology, Duke University School of Medicine, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-240279_ref1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","article-title":"Alzheimer\u2019s disease","volume":"388","author":"Scheltens","year":"2016","journal-title":"Lancet"},{"key":"10.3233\/JAD-240279_ref2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","article-title":"Amyloid-beta and tau: The trigger and bullet in Alzheimer disease pathogenesis","volume":"71","author":"Bloom","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-240279_ref3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-beta biomarkers for Alzheimer\u2019s disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"10.3233\/JAD-240279_ref4","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","article-title":"Tau biomarkers in Alzheimer\u2019s disease: Towards implementation in clinical practice and trials","volume":"21","author":"Ossenkoppele","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-240279_ref5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: Towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-240279_ref6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-240279_ref7","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.3233\/JAD-215639","article-title":"Blood phosphorylated tau 181 as a biomarker for amyloid burden on brain PET in cognitively healthy adults","volume":"87","author":"McGrath","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240279_ref8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3928\/23258160-20191031-06","article-title":"Correlation of OCTA and volumetric MRI in mild cognitive impairment and Alzheimer\u2019s disease","volume":"50","author":"Yoon","year":"2019","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.3233\/JAD-240279_ref9","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3928\/23258160-20210528-06","article-title":"Assessing the retinal microvasculature in individuals with early and late-onset Alzheimer\u2019s disease","volume":"52","author":"Robbins","year":"2021","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.3233\/JAD-240279_ref10","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3928\/23258160-20180601-09","article-title":"Assessment of differences in retinal microvasculature using OCT angiography in Alzheimer\u2019s disease: A twin discordance report","volume":"49","author":"Grewal","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.3233\/JAD-240279_ref11","doi-asserted-by":"crossref","first-page":"100899","DOI":"10.1016\/j.preteyeres.2020.100899","article-title":"Retinal changes in Alzheimer\u2019s disease- integrated prospects of imaging, functional and molecular advances","volume":"82","author":"Gupta","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"10.3233\/JAD-240279_ref12","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00401-016-1613-6","article-title":"Ocular indicators of Alzheimer\u2019s: Exploring disease in the retina","volume":"132","author":"Hart","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-240279_ref13","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3233\/JAD-230167","article-title":"Vitreous humor biomarkers reflect pathological changes in the brain for Alzheimer\u2019s disease and chronic traumatic encephalopathy","volume":"93","author":"Vig","year":"2023","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240279_ref14","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.3233\/JAD-181104","article-title":"Association of cognitive function with amyloid-beta and tau proteins in the vitreous humor","volume":"68","author":"Wright","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240279_ref15","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1167\/iovs.18-24694","article-title":"Ocular biomarkers of Alzheimer\u2019s disease: The role of anterior eye and potential future directions","volume":"59","author":"Dehghani","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.3233\/JAD-240279_ref16","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(03)12981-9","article-title":"Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer\u2019s disease","volume":"361","author":"Goldstein","year":"2003","journal-title":"Lancet"},{"key":"10.3233\/JAD-240279_ref17","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3233\/JAD-2010-100210","article-title":"Differential accumulation of secreted AbetaPP metabolites in ocular fluids","volume":"20","author":"Prakasam","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240279_ref18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5301\/EJO.2010.2108","article-title":"Detection of Alzheimer peptides and chemokines in the aqueous humor","volume":"21","author":"Janciauskiene","year":"2011","journal-title":"Eur J Ophthalmol"},{"key":"10.3233\/JAD-240279_ref19","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/0145482X1010400606","article-title":"Sensitivity and specificity of the Montreal Cognitive Assessment modified for individuals who are visually impaired","volume":"104","author":"Wittich","year":"2010","journal-title":"J Vis Impair Blind"},{"key":"10.3233\/JAD-240279_ref21","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/2211068215589580","article-title":"The Simoa HD-1 analyzer: A novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing","volume":"21","author":"Wilson","year":"2016","journal-title":"J Lab Autom"},{"key":"10.3233\/JAD-240279_ref23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/acn3.50972","article-title":"Confounding effect of blood volume and body mass index on blood neurofilament light chain levels","volume":"7","author":"Manouchehrinia","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.3233\/JAD-240279_ref24","doi-asserted-by":"crossref","first-page":"1027705","DOI":"10.3389\/fnagi.2022.1027705","article-title":"Association of cognitive function with neurofilament light chain in the aqueous humor of human eye","volume":"14","author":"Bai","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JAD-240279_ref25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/08820538.2021.1883679","article-title":"Highly expressed amyloid beta-42 of aqueous humor in patients with neovascular macular degeneration","volume":"36","author":"Zhu","year":"2021","journal-title":"Semin Ophthalmol"},{"key":"10.3233\/JAD-240279_ref26","doi-asserted-by":"crossref","first-page":"e0159099","DOI":"10.1371\/journal.pone.0159099","article-title":"Estimation of tau and phosphorylated tau181 in serum of Alzheimer\u2019s disease and mild cognitive impairment patients","volume":"11","author":"Shekhar","year":"2016","journal-title":"PLoS One"},{"key":"10.3233\/JAD-240279_ref27","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"key":"10.3233\/JAD-240279_ref28","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240279_ref29","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/alz.12313","article-title":"Ophthalmic conditions associated with dementia risk: The Cardiovascular Health Study","volume":"17","author":"Hwang","year":"2021","journal-title":"Alzheimers Dement"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-240279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:58:27Z","timestamp":1777370307000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-240279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":27,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jad-240279","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]}}}